CO2023005218A2 - Nanopartículas lipídicas para administrar vacunas de arnm - Google Patents

Nanopartículas lipídicas para administrar vacunas de arnm

Info

Publication number
CO2023005218A2
CO2023005218A2 CONC2023/0005218A CO2023005218A CO2023005218A2 CO 2023005218 A2 CO2023005218 A2 CO 2023005218A2 CO 2023005218 A CO2023005218 A CO 2023005218A CO 2023005218 A2 CO2023005218 A2 CO 2023005218A2
Authority
CO
Colombia
Prior art keywords
lipid nanoparticles
mrna vaccines
deliver mrna
deliver
mrna
Prior art date
Application number
CONC2023/0005218A
Other languages
English (en)
Spanish (es)
Inventor
Danilo Casimiro
Sudha Chivukula
Frank Derosa
Anusha Dias
Rebecca L Goldman
Hardip Rajeshbhai Gopani
Kirill Kalnin
Shrirang Karve
Asad Khanmohammed
Priyal Patel
Timothy Plitnik
Ashish L Sarode
Timothy Tibbitts
Khang Anh Tran
Montoya Natalia Vargas
Angela Lynne Beaulieu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/058250 external-priority patent/WO2022099003A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2023005218A2 publication Critical patent/CO2023005218A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2023/0005218A 2020-11-06 2023-04-25 Nanopartículas lipídicas para administrar vacunas de arnm CO2023005218A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063110965P 2020-11-06 2020-11-06
US202163212523P 2021-06-18 2021-06-18
EP21315198 2021-10-13
PCT/US2021/058250 WO2022099003A1 (en) 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines

Publications (1)

Publication Number Publication Date
CO2023005218A2 true CO2023005218A2 (es) 2023-05-19

Family

ID=86184333

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0005218A CO2023005218A2 (es) 2020-11-06 2023-04-25 Nanopartículas lipídicas para administrar vacunas de arnm

Country Status (9)

Country Link
EP (1) EP4240335A1 (https=)
JP (1) JP7817257B2 (https=)
KR (1) KR20230104223A (https=)
CN (1) CN116406299A (https=)
AU (1) AU2021374976A1 (https=)
CA (1) CA3194325A1 (https=)
CO (1) CO2023005218A2 (https=)
IL (1) IL302631A (https=)
MX (1) MX2023005203A (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
EP4612301A1 (en) * 2022-11-03 2025-09-10 ModernaTX, Inc. Chemical stability of mrna
CN118021957A (zh) * 2022-11-11 2024-05-14 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
CN118021956A (zh) * 2022-11-11 2024-05-14 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
WO2025054383A1 (en) * 2023-09-06 2025-03-13 Modernatx, Inc. Chemical stability of mrna
WO2025092866A1 (zh) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗
CN120053395A (zh) * 2023-11-30 2025-05-30 苏州维益生物科技有限公司 含二硫键的核酸-脂质颗粒、药物、用途、及制备方法
CN118725043B (zh) * 2024-06-27 2025-12-05 中国人民解放军陆军军医大学 用于递送核酸的多肽-脂质组合物及其应用和mRNA疫苗
CN119746089B (zh) * 2025-03-07 2025-06-13 细胞生态海河实验室 脂质纳米颗粒冷冻保护剂
CN121466311A (zh) * 2026-01-09 2026-02-06 羿美诚健(上海)生物医药有限公司 一种脂质组合物及其在核酸递送中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143848A1 (en) * 2014-03-24 2017-05-25 Shire Human Genetic Therapies, Inc. Mrna therapy for the treatment of ocular diseases
ES2949540T3 (es) * 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
TW202309002A (zh) * 2021-04-15 2023-03-01 美商轉譯生技公司 基於「古德」緩衝液的陽離子脂質

Also Published As

Publication number Publication date
MX2023005203A (es) 2023-07-13
IL302631A (en) 2023-07-01
JP7817257B2 (ja) 2026-02-18
CA3194325A1 (en) 2022-05-12
AU2021374976A1 (en) 2023-06-29
CN116406299A (zh) 2023-07-07
KR20230104223A (ko) 2023-07-07
JP2023550600A (ja) 2023-12-04
EP4240335A1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
CO2023005218A2 (es) Nanopartículas lipídicas para administrar vacunas de arnm
MX2024001138A (es) Arn guia modificados.
MX2023006604A (es) Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos.
CL2020002053A1 (es) Métodos y composiciones para polarización de macrófagos.
CO2020014645A2 (es) Moléculas de unión contra bcma y usos de las mismas
MX2021009118A (es) Composiciones y metodos para inhibir la expresion del gen alas1.
CO2025000009A2 (es) Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
MX2019012280A (es) Composiciones dirigidas.
AR113490A1 (es) CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
CO2021017544A2 (es) Composiciones y métodos para la regulación génica selectiva
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
SV2015005107A (es) Composiciones y métodos para activar la señalización que depende del estimulador del gen de interferon
GT201500330A (es) Composiciones y métodos de uso de interferencia de arn en serpina 1
CR20170174A (es) Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b
ES2689523T3 (es) Composiciones a base de ARNM del gen CFTR y métodos y usos relacionados
MX392977B (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
AR093291A1 (es) Celulas con genes neuroendocrinos modificados
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
MX2016013950A (es) Metodo para producir l-aminoacidos utilizando una bacteria alcalifilica.
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
MX383117B (es) Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
MX2017011298A (es) Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53.
MX2018006373A (es) Produccion de virus en cultivos celulares.
MX2025009057A (es) Nanoparticulas lipidicas conjugadas con anticuerpos especificos de cmh y usos de las mismas